While adoption of blockchain is on the rise, lack of skilled staff is hampering its development in the life science industry, finds survey from The Pistoia Alliance
27 September, 2018
Focus is now on 39 centrally authorised medicines, down from 108
26 September, 2018
Urgent need to scale up newer tools available today to save lives; and develop a fast, safe and simple cure for TB
25 September, 2018
Solna, Sweden, September 24, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that a major Nordic study (“Affibody-3”) will begin using Affibody’s PET imaging agent ABY-025. ABY-025 is a novel Affibody® molecule imaging tracer that with high precision can identify HER2 status in breast cancer patients. The researchers will be investigating a new ABY-025 based method developed at Uppsala University and the PET center at Uppsala University Hospital that has the potential to improve personalized breast cancer treatment.
24 September, 2018
The topic of this month’s newsletter from Drug Discovery Today is “Drug Delivery”.
19 September, 2018
Optibrium, Intellegens and Medicines Discovery Catapult awarded funding to apply machine learning in drug discovery
19 September, 2018
Tattoos have definitely become mainstream, but possible dangers from tattoo inks include bacterial contamination, allergies, toxic effects and eventually the risk of cancer. Two in three people report side-effects after getting a tattoo. Even the new proposals developed by the European Chemical Agency (ECHA) are insufficient to guarantee safe inks without risk of toxicity and cancerogenicity. At the EADV Congress which opened today in Paris, the EADV reiterates its demand that tattoo inks should be properly tested and should at least meet the same safety standards as cosmetic products.
15 September, 2018
Thermo Fisher Scientific and Diamond Light Source are creating a step change for life sciences sector, a one-stop shop for structural biology and one of largest cryo-EM sites in the world.
14 September, 2018
Leading topical and transdermal delivery specialist MedPharm Ltd have announced the appointments of Dr Jon Lenn to the position of Chief Technology Officer (CTO) and Dr Haydn Sinclair to the role of Vice President of Pharmaceutical Quality with Global Responsibilities.
02 September, 2018
Blood vessels sustain health and proper functioning of our body. A multi-disciplinary team of scientists, led by prof. Peter Carmeliet (VIB-KU Leuven Center for Cancer Biology) has made several breakthrough discoveries concerning the metabolism of the individual building blocks of blood vessels - the so-called endothelial cells. They identified three key proteins that determine how blood vessels grow and behave, and that may become new therapeutic targets in blood vessel related disorders, such as life-threatening cancers and blinding eye diseases. For his pioneering research, Peter Carmeliet will receive the most prestigious international science prize, 2018 Heineken Prize for Medicine.
01 September, 2018